FDA clears study of Neuralstem spinal cord therapy

Published: 09:34:31 PM, Mon 14 January 2013 UTC

NEW YORK (AP) — Adult stem cell developer Neuralstem Inc. said Monday the Food and Drug Administration approved the company's plan for a small, early-stage study of its treatment for spinal cord injury.

The company plans to enroll up to eight patients with a type of spinal cord injury that causes complete paralysis.

All patients in the study will receive six injections of stem cells, followed by physical therapy and drugs to prevent the body from rejecting the stem cells.

Neuralstem is studying several therapeutic uses of adult stem cells. The company completed phase I testing of a treatment for Lou Gehrig's disease in August.

Shares of Neuralstem Inc. rose 5 cents, or 4 percent, to close at $1.29.

Tags: new york yankees, lou gehrig, fda, neuralstem inc., patients, cents, health, monday, drug administration, study, drugs, percent, company, treatment, food, new york, phase, stem cells, stem cell, cell division, physical therapy, spinal cord injury, spinal cord, spinal cord therapy, injections, early-stage study, amyotrophic lateral sclerosis, adult stem, stem cell developer, adult stem cells, complete paralysis, therapeutic uses, adult stem cell, cellular differentiation